EA202090053A2 - Способы и композиции для лечения неэффективного эритропоэза - Google Patents

Способы и композиции для лечения неэффективного эритропоэза

Info

Publication number
EA202090053A2
EA202090053A2 EA202090053A EA202090053A EA202090053A2 EA 202090053 A2 EA202090053 A2 EA 202090053A2 EA 202090053 A EA202090053 A EA 202090053A EA 202090053 A EA202090053 A EA 202090053A EA 202090053 A2 EA202090053 A2 EA 202090053A2
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
erythropoesis
compositions
effective
treating non
Prior art date
Application number
EA202090053A
Other languages
English (en)
Other versions
EA202090053A3 (ru
Inventor
Джасбир СИХРА
Роберт Скотт Пирсалл
Равиндра КУМАР
Нага Венката Саи Раджасекхар Сурагани
Original Assignee
Акселерон Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акселерон Фарма Инк. filed Critical Акселерон Фарма Инк.
Publication of EA202090053A2 publication Critical patent/EA202090053A2/ru
Publication of EA202090053A3 publication Critical patent/EA202090053A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Настоящее изобретение относится к способам лечения неэффективного эритропоэза у пациента, включающим введение пациенту полипептида ActRIIB, по меньшей мере на 90% идентичного последовательности из 109 аминокислот SEQ ID NO: 1, где указанный полипептид содержит кислую аминокислоту в положении 79.
EA202090053A 2011-10-17 2012-10-17 Способы и композиции для лечения неэффективного эритропоэза EA202090053A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17

Publications (2)

Publication Number Publication Date
EA202090053A2 true EA202090053A2 (ru) 2020-04-30
EA202090053A3 EA202090053A3 (ru) 2020-06-30

Family

ID=48141315

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201490809A EA034563B1 (ru) 2011-10-17 2012-10-17 Способ лечения или предотвращения перегрузки железом у пациента с талассемией
EA202090053A EA202090053A3 (ru) 2011-10-17 2012-10-17 Способы и композиции для лечения неэффективного эритропоэза

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201490809A EA034563B1 (ru) 2011-10-17 2012-10-17 Способ лечения или предотвращения перегрузки железом у пациента с талассемией

Country Status (13)

Country Link
US (4) US20130243743A1 (ru)
EP (3) EP2797620B1 (ru)
JP (4) JP6092883B2 (ru)
KR (4) KR20200019261A (ru)
CN (3) CN107693776A (ru)
AU (4) AU2012326207B2 (ru)
BR (3) BR122019023174B1 (ru)
CA (1) CA2852683A1 (ru)
DK (1) DK3520805T3 (ru)
EA (2) EA034563B1 (ru)
ES (2) ES2869168T3 (ru)
HK (3) HK1203413A1 (ru)
WO (1) WO2013059347A1 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891010C (en) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR20140137463A (ko) 2007-02-01 2014-12-02 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
EP3805259A1 (en) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
CN104936605A (zh) 2012-11-02 2015-09-23 细胞基因公司 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
US20160046690A1 (en) * 2014-03-21 2016-02-18 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA2962197C (en) * 2014-04-18 2023-10-03 Ravindra Kumar Methods for increasing red blood cell levels and treating sickle-cell disease
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016090077A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
EP3286206B1 (en) 2015-04-22 2021-02-17 Biogen MA Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
KR102640198B1 (ko) * 2015-05-13 2024-02-23 셀진 코포레이션 Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료
CA2986432A1 (en) 2015-05-20 2016-11-24 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
WO2017079591A2 (en) * 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
US11267865B2 (en) * 2016-10-05 2022-03-08 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
AU2017357944A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
WO2018231905A1 (en) 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
AU716893B2 (en) 1995-04-11 2000-03-09 General Hospital Corporation, The Reverse two-hybrid systems
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
WO2000043781A2 (en) 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
ZA200503024B (en) * 2002-10-15 2006-11-29 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
CA2891010C (en) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) * 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
CN113577291A (zh) * 2009-08-13 2021-11-02 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

Also Published As

Publication number Publication date
HK1203413A1 (en) 2015-10-30
HK1252940A1 (zh) 2019-06-06
CN107693776A (zh) 2018-02-16
AU2017201580B2 (en) 2018-07-12
JP2017101060A (ja) 2017-06-08
KR20140084211A (ko) 2014-07-04
AU2012326207A1 (en) 2014-05-15
ES2741477T3 (es) 2020-02-11
JP2020186277A (ja) 2020-11-19
US20170137791A1 (en) 2017-05-18
EP3875104A1 (en) 2021-09-08
US20210207107A1 (en) 2021-07-08
JP6092883B2 (ja) 2017-03-08
ES2869168T3 (es) 2021-10-25
KR20220075438A (ko) 2022-06-08
BR112014009528A2 (pt) 2017-05-09
AU2020286229A1 (en) 2021-01-07
EA202090053A3 (ru) 2020-06-30
BR122019023174B1 (pt) 2021-02-23
EA034563B1 (ru) 2020-02-20
BR112014009528A8 (pt) 2019-12-10
HK1250341A1 (zh) 2018-12-14
BR122019023166B1 (pt) 2021-02-23
JP2014530253A (ja) 2014-11-17
CA2852683A1 (en) 2013-04-25
EP2797620A4 (en) 2015-05-20
WO2013059347A1 (en) 2013-04-25
EP2797620B1 (en) 2019-04-24
EP3520805B1 (en) 2021-03-10
CN103987403A (zh) 2014-08-13
JP6383821B2 (ja) 2018-08-29
CN107837390A (zh) 2018-03-27
AU2017201580A1 (en) 2017-03-30
DK3520805T3 (da) 2021-04-19
AU2018247262A1 (en) 2018-11-01
US20130243743A1 (en) 2013-09-19
KR20200019261A (ko) 2020-02-21
US20170327800A1 (en) 2017-11-16
JP6796626B2 (ja) 2020-12-09
EP3520805A1 (en) 2019-08-07
EA201490809A1 (ru) 2014-09-30
EP2797620A1 (en) 2014-11-05
BR112014009528B1 (pt) 2020-12-29
AU2012326207B2 (en) 2016-12-15
AU2018247262B2 (en) 2020-12-24
CN103987403B (zh) 2017-12-01
KR102079482B1 (ko) 2020-02-19
JP2018165287A (ja) 2018-10-25
KR20190105113A (ko) 2019-09-11

Similar Documents

Publication Publication Date Title
EA202090053A2 (ru) Способы и композиции для лечения неэффективного эритропоэза
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
IN2014KN01715A (ru)
IN2014KN01713A (ru)
IN2014KN01714A (ru)
IN2014KN01716A (ru)
MX346206B (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
IN2014CN04498A (ru)
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
EA201391387A1 (ru) Нейропротекторные пептиды
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112014018106A2 (pt) composto, uso de um composto, e, método para tratar uma doença fibrótica